XML 23 R12.htm IDEA: XBRL DOCUMENT
v3.19.1

Note 6 - Investment in and Transactions with Unconsolidated Subsidiaries | 3 Months Ended
--- | ---
Mar. 31, 2019
Notes to Financial Statements |
Equity Method Investments and Joint Ventures Disclosure [Text Block] | NOTE 6 – INVESTMENT IN AND TRANSACTIONS WITH UNCONSOLIDATED SUBSIDIARIES Milestone China Ltd. Ownership In June 2014, Milestone Scientific invested $1 million in Milestone China Ltd. (“Milestone China”) by contributing 772 STA Instruments to Milestone China for a 40% ownership interest. Milestone Scientific recorded this investment under the equity method of accounting. Related Party Transactions Milestone China is Milestone Scientific’s exclusive distributor in China. During 2017 and prior to the payment default during 2018 Milestone Scientific agreed to sell inventory to Milestone China and its agent. During 2018 Milestone Scientific entered into a payment arrangement with Milestone China to satisfy past due receivables from Milestone China and it’s agents which increased to $ 2.8 million at the time of the payment arrangement. The payment terms required $200,000 payments per month beginning in July 2018 through November 2018 and a balloon payment of approximately $1,425,000 during December 2018. Milestone Scientific only collected $950,000 under the payment arrangement which resulted in a deferred revenue and deferred cost balance of $1.8 million and $1.25 million. Due to the default on the arrangement and Milestone China’s liquidity constraints, Milestone Scientific halted shipments to Milestone China. The Company has adjusted the accounts receivable related party and the deferred revenue related party based on the expected payment realization and recorded a reserve against the related deferred cost of $1.25 million. As of March 31, 2019, Milestone Scientific has deferred revenues and deferred costs associated with sales to Milestone China and it’s agents of $50,000 and $24,602, respectively. As of December 31, 2018, Milestone Scientific had deferred revenues and deferred costs associated with sales to Milestone China and it’s agents of $100,000 and $50,000, respectively. Milestone Scientific recognized $50,000 of related party sales of handpieces to Milestone China and its agent for the three months ended March 31, 2019. For the three months ending Mach 31, 2018, Milestone recognized no sales to Milestone China and its agent. Gross Profit Deferral Due to timing differences of when the inventory sold to Milestone China is recognized and when Milestone China sells the acquired inventory to third parties, an elimination of the profit is required as of the balance sheet date. In accordance with ASC 323 Equity Method and Joint Ventures, Milestone Scientific has deferred 40% of the gross profit associated with recognized revenue from sales to Milestone China until that product is sold to third parties. At March 31, 2019 and December 31, 2018 , the deferred profit was $431,364 and $421,800, respectively, which is included in deferred profit, related party in the condensed consolidated balance sheets. For the three months ended March 31, 2019 and 2018, Milestone Scientific recorded a loss and income on equity investment of $9,564 and $36,783, respectively, for product sold by Milestone China to third parties. Equity Method Disclosures As March 31,2019 and December 31, 2018, Milestone Scientific's investment in Milestone China was $0. As of March 31,2019 and December 31, 2018, Milestone Scientific’s share of cumulative losses of Milestone China were $3,984,177 and $3,380,388, respectively, which have been suspended. The following table includes summarized financial information (unaudited) of Milestone China:
|  | March 31, 2019 |  |  | December 31, 2018 |
Assets: |  | (unaudited) |  |  | (unaudited) |
Current assets |  | $ | 12,989,534 |  |  | $ | 10,587,648 |
Non-current assets |  |  | 4,604,255 |  |  |  | 4,603,485 |
Total assets: |  | $ | 17,593,789 |  |  | $ | 15,191,133 |
Liabilities: |  |  |  |  |  |  |  |
Current liabilities |  |  | 21,914,957 |  |  |  | 17,696,033 |
Stockholders' equity (deficit) |  |  | (4,321,168 | ) |  |  | (2,504,900 | )
Total liabilities and stockholders’ deficit |  | $ | 17,593,789 |  |  | $ | 15,191,133 |
|  | March 31, 2019 |  |  | March 31, 2018 |
|  | (unaudited) |  |  | (unaudited) |
Net sales |  | $ | 604,328 |  |  | $ | 756,956 |
Cost of goods sold |  |  | 235,100 |  |  |  | 447,611 |
Gross profit |  |  | 369,228 |  |  |  | 309,345 |
Other expenses |  |  | (1,878,704 | ) |  |  | (1,252,213 | )
Net loss |  | $ | (1,509,476 | ) |  | $ | (942,868 | )

X
- References No definition available. + Details
Name: | us-gaap_DisclosureTextBlockAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section S99 -Paragraph 4 -Subparagraph (SX 210.3A-04) -URI http://asc.fasb.org/extlink&oid=116822174&loc=d3e355119-122828 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -URI http://asc.fasb.org/topic&trid=2196965 + Details
Name: | us-gaap_EquityMethodInvestmentsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration